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In regards to bioterrorism, the goal of the
U.S. Food and Drug Administration (FDA) is to
foster the development of vaccines, drugs and
diagnostic products, safeguards of the food
supply, and other measures needed to respond to
bioterrorist threats. Many products (vaccines,
therapeutic drug and biological products, food,
devices, and diagnostics) regulated by FDA could
be affected by bioterrorism. Pathogens or pathogen
products adapted for biological warfare include
smallpox (variola), anthrax (Bacillus anthracis),
plague (Yersinia pestis), tularemia (Francisella
tularensis), brucellosis (Brucella abortus,
B. melitensis, B. suis, B. canis), Q fever (Coxiella
burnettii), botulinum toxin (produced by
Clostridium botulinum) and staphylococcal en-
terotoxin B. New products are needed to diagnose,
prevent, and treat these public health threats.
FDA is participating in an interagency group
preparing for response in a civilian emergency.
This group includes representatives of the
Department of Defense; the Veterans Adminis-
tration; and components of the Department of
Health and Human Services (DHHS), such as
the Centers for Disease Control and Prevention
(CDC), National Institutes of Health (NIH), and
Office of Emergency Preparedness. In addition,
FDA will be proposing standards for the use of
animal efficacy data in approving new products
to counter chemical and biological agents. The
agency is also participating in setting a broad-
based federal research agenda to facilitate the
governments preparedness against bioterrorism;
is identifying facilities and activities suitable for
the production of biological weapons; is involved
in product development, review, and testing; and is
ensuring that appropriate product surveillance
and sponsor compliance are executed in
accordance with regulations.
FDAs regulation of medical products is
based on science, law, and public health
considerations (Figure 1). Research conducted at
FDA (in particular at the Center for Biologics
Evaluation and Research) contributing to
biological warfare defense and other
counterbioterrorism efforts is in the following
areas: design of new vaccines (e.g., pox viruses);
pathogenesis and mechanism of replication of
biological warfare agents; new methods and
standards to expedite the review of new vaccines
and immunoglobulins (e.g., mucosal protection
against a pathogen); and stem cell protection and
chemokine/cytokine and angiogenic agent defense
mechanisms. The development framework of
most biological and traditional drug products is
shown in Figure 2. The principal evaluation and
research and development phases before a drug
is submitted to FDA for approval can take 1 to 3
years. The clinical research and development
program (investigational phase), depending on
the agent and clinical indication, can take 2 to 10
years. The marketing application review period
generally is 2 months to 3 years (average 1 year).
Once a product is approved, long-term
postmarketing surveillance, inspections, and
product testing are performed to ensure the
quality, safety, and efficacy of the product, as
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Figure 1. Regulation of medical products.
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well as appropriate product labeling. Accelerating
product development is important in many
situations, including bioterrorism. Mechanisms
for advancing medicines through the approval
process have been developed for severe and life-
threatening illnesses. For drugs and biologic
products, these mechanisms include expedited
review and fast-track development, as well as
accelerated approval and priority review of
marketing applications. For a priority product,
complete review of marketing applications is
6 months.
Many of the biological warfare defense
products pose difficult problems with regard to
obtaining clinical efficacy data. For many of
these infectious agents or toxins, human efficacy
trials cannot be performed, as such studies would
involve exposing healthy human volunteers to a
lethal or permanently disabling agent without
proven therapy and field trials. In most cases,
such trials are not feasible because pockets of
natural exposure do not exist. To address this
dilemma, FDA will be proposing that the use of
animal efficacy data be allowed when appropri-
ate (1). This proposed rule would identify the
types of data required. Safety, pharmacokinetic,
and immunogenicity data will still be necessary
in humans. Product safety will likely be evaluated
in healthy human volunteers at doses and routes of
administration anticipated in field use.
Some scientific considerations for animal
studies include the toxic agents pathophysi-
ologic mechanism of toxicity and how the test
drug or biologic product prevents it and the
validity of the animal study endpoint in humans.
In addition, data showing that drug effectiveness
in animals predicts efficacy in humans would be
needed. Finally, product recipients should be
given follow-up after treatment to affirm product
safety and efficacy.
For licensure or other approval, a biological
warfare defense product must have an accept-
able quality, safety, efficacy, and potency profile.
Likewise, the product must have acceptable stability
characteristics and be produced in compliance with
current good manufacturing practices.
A case study of anthrax vaccine can serve as
an example of our capability to respond to a
bioterrorist threat. Only one licensed anthrax
vaccine (Bioport Corp.) is available. This vaccine
consists of a membrane-sterilized culture filtrate
of B. anthracis V770-NP1-R, an avirulent,
nonencapsulated strain. The culture filtrate is
adsorbed to aluminum hydroxide and formu-
lated with benzethonium chloride (preservative)
and formaldehyde (stabilizer). The administra-
tion schedule consists of 0.5 ml injected
subcutaneously at 0, 2, and 4 weeks, 6, 12, and 18
months, and then annually thereafter. The
vaccine was licensed in 1970. The efficacy data in
support of the license consisted of a single-blind,
well-controlled field study (2). The vaccine
efficacy was 92.5% (lower 95% confidence limit of
65%). Of the 26 cases of anthrax in this study, 21
were cutaneous and 5 (4 fatal) were inhalation (2
in the placebo group, 0 in the vaccinated group,
3 in the unvaccinated group).
¯
Figure 2. Development of biological and tradition
drug products.
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In December 1985, the Federal Register (3)
published the FDAs advisory panel review of the
efficacy of anthrax adsorbed. The panel
recommended that this product be placed in
category I (safe, effective, and not misbranded)
and that the appropriate license be continued
because there was substantial evidence for this
product.
Studies of new anthrax vaccine products are
in progress. They include protective antigen
based vaccines, e.g., purified protein from
B. anthracis culture or live-attenuated spore
vaccine. Production and product testing will
differ for each of these candidate vaccines. The
immunogenicity of the product in humans and
animal models should be assessed. The cell-
mediated immunity elicited by the vaccine may
also need to be evaluated. One of the immune
correlates of protection of anthrax vaccines is
likely to be the antibody response to protective
antigen. However, the quantitative relation of
antiprotective antigen antibody to protection has
not been established in humans but is being
investigated by the Department of Defense.
Animal challenge and protection models,
especially rabbit and nonhuman primate models,
may be particularly useful. Passive transfer of
protection, also an indication of the importance
of antibodies for protection, has been observed in
animal models. Therefore, human challenge
protection studies and new field efficacy trials
are not feasible in studying the efficacy of new
anthrax vaccines. Animal challenge and protec-
tion studies against spores will be important for
new vaccines based on protective antigen.
Comparisons of immune responses in human
cohorts receiving new or licensed vaccines
should be performed.
Data should be obtained on various target
populations, including adults and children, to
evaluate the safety of new anthrax vaccines.
Systemic and local adverse events are particu-
larly important to monitor. For live-attenuated
and vector vaccine approaches, the potential for
transmission to others will be an important
consideration in clinical development and use.
After these vaccines are licensed and adminis-
tered, the safety and adverse reactions of these
vaccines should be assessed.
In conclusion, FDA will be providing a
critical link in access of new medicines for
biowarfare defense (Table). The expected out-
comes of these activities include safe and
Table. Proposed activities of the U.S. Food and Drug
Administration to counter bioterrorism
1. Enhancing the expeditious development and
licensure of new vaccines and biological
therapeutics through research and review
activitiesanthrax vaccine and antisera to
botulinum toxin, for example.
2. Enhancing the timeliness of application reviews
of new drugs and biological products and new
uses of existing products.
3. Participating in the planning and coordination of
public health and medical response to a terrorist
attack involving a biological or chemical agent(s).
4. Participating in the development of rapid
detection and decontamination for agents of
bioterrorism such as Clostridium botulinum
toxins,  Yersinisa pestis, Bacillus anthracis.
5. Ensuring the safety of regulated foods, drugs,
medical devices, and biological products; arrange
for seizure and disposal of affected products.
6. Developing techniques for detection of genetic
modifications of microorganisms to make them
more toxic or antibiotic- or vaccine-resistant.
7. Rapidly determining a microbes sensitivity to
drug therapy.
8. Determining the mechanism of replication and
pathogenicity or virulence of identified organisms
including elements that can be transferred to
other organisms to circumvent detection,
prevention, or treatment.
9. Enhancing adverse product reporting surveillance
capabilities.
effective products to treat or prevent toxicity of
biological and chemical agents; methods to
rapidly detect, identify, and decontaminate
hazardous organisms; a greater ability to ensure
the safety of the food supply; and a greater ability
to provide appropriate medical care and a public
health response.
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